University Trial Confirms Persist® PAF Enhances Plant-Beneficial Microbes
Article content
VGrid partnered with Wageningen University and Research, a global leader in controlled-environment agriculture, to conduct this hydroponics tomato cultivation trial.
Article content
CAMARILLO, Calif. — A recent university study found that Persist® PAF, a liquid enhancer for plants and soil, boosts the growth of beneficial microbes in biochar—leading to lasting improvements in the root zone of hydroponic tomato plants.
Article content
The study, conducted in the Netherlands, compared pistachio shell biochar—produced by VGrid's Bioserver® units—with standard coir slabs, untreated biochar, acetic acid-treated biochar, and biochar pre-treated with PAF. Researchers evaluated microbial activity in both the growing medium and tomato rhizosphere over a 23-week cultivation period using advanced qPCR and DNA metabarcoding methods.
Article content
In the trial, PAF-treated biochar showed significantly higher levels of beneficial bacteria—especially those involved in nutrient cycling and plant resilience—compared to untreated or acid-only treatments. The result is a more biologically active root zone that supports better plant growth and productivity.
Article content
Key Findings:
Article content
compared to all other substrates, including coir, untreated biochar, and biochar treated with acetic acid.
Article content
The bacterial phyla Nitrospirae and Firmicutes
Article content
, which are known to promote nutrient cycling and plant resilience, were substantially more abundant in the PAF-treated biochar.
Article content
PAF had a lasting impact on the microbiome of the biochar substrate and the tomato rhizosphere
Article content
, resulting in a more diverse and beneficial bacterial community throughout the cultivation period.
Article content
These findings highlight the potential of PAF to enhance crop and soil productivity, reduce reliance on synthetic inputs, and advance sustainable, organic, and regenerative agriculture.
Article content
Jeff Norton, Vice President of Business Development with VGrid, commented, 'We're excited with these results. They further confirm what we've seen in previous trials and the field—PAF improves plant vigor and drives positive change to the microbiome. The PAF-treated biochar also significantly outperformed acetic acid-treated biochar, showing that PAF's benefits aren't just about lowering pH—its unique chemistry is driving the results.'
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
6 hours ago
- National Post
Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025
Article content BAAR, Switzerland — Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow (United Kingdom) June 13-16. Article content The company will present 25 posters and host two scientific symposia during which six world-leading experts will share their insight on respiratory and food allergy: Article content 'Breath of change: redefining respiratory allergy care with remission in sight': with environmental change impacting respiratory allergies, a new approach to disease management is necessary. Clinical remission is emerging as a relevant treatment goal for Type 2 allergies and allergen immunotherapy (AIT) has the potential to cater to this approach. Article content ' Myth busting in peanut allergy: separating fact from fiction ': misconceptions about food allergy management may influence treatment decisions, thus underscoring the vital role of patient-clinician communication. Article content ' We are enthusiastic to share how Stallergenes Greer is bolstering its impact in the field of respiratory and food allergy. Our research findings highlighted at the symposia, as well as through scientific posters and presentations, reflect our determination to deliver innovative allergen immunotherapy solutions that offer sustained benefits for patients worldwide,'stated Dr Elena Rizova, Chief Medical Officer, Stallergenes Greer. ' Our portfolio offers a broad range of proven treatment solutions designed to provide long-lasting relief for patients with allergies across a spectrum of conditions ranging from allergic rhinitis and asthma to food allergy.' Article content The presentation of the posters will showcase Stallergenes Greer's latest research efforts and reaffirm its commitment to advancing personalised allergy care for the benefit of patients and healthcare professionals. Topics include patient benefits with AIT and its potential for clinical remission, new data from the recent real-world study VORAN on 300 IR House Dust Mite (HDM) SLIT tablet, PDAH (defatted powder of Arachis Hypogaea L., semen [peanut]) allergen consistency compared to supermarket peanut products, and prevention of food-induced anaphylaxis in children, including toddlers. Article content Chair: Prof. Adnan Custovic, United Kingdom Article content POSTERS Article content Among the topics covered by the 25 posters, specific findings will be presented and discussed in depth: Article content Recent findings highlight the potential of Stallergenes Greer immunotherapies to provide sustained symptom relief and reduce reliance on corticosteroids even after treatment cessation, aligning with the concept of clinical remission on and off treatment. Evidence from VORAN, the first European real-world data generation study with 300 IR HDM SLIT tablet, supports the safety profile and effectiveness of this treatment in HDM-induced allergic rhinitis with or without controlled asthma in more than 700 adults and adolescents, with over 80% having improved their symptoms and sleep and almost 2/3 stopping nasal corticosteroid use. These findings are further supported by the PRACTIS study, where the benefits of SLIT-liquid met expectations in approximately 90% of patients with allergic rhino conjunctivitis and/or asthma. Article content Furthermore, Stallergenes Greer recently conducted studies showing that its peanut allergy treatment, PDAH, is consistent and offers a positive risk-benefit ratio. Unlike common peanut products found in supermarkets, which can vary in protein and allergen levels, PDAH shows consistency across batches. The research also points to an opportunity to help children from 1 year, when their immune systems may be more adaptable. In clinical studies, the treatment helped reduce the risk of accidental allergic reactions and showed a solid safety record, especially in toddlers. Article content ABOUT THE EAACI CONGRESS Article content The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 16,000 members from 125 countries and over 50 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy. Article content Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. Article content Article content Article content Article content Contacts Article content Stallergenes Greer Article content Article content
CBC
10 hours ago
- CBC
Squamish fire, Vancouver warning?
The Dryden Creek fire north of Squamish, B.C., is just the latest blaze burning near a city. As wildfires get closer to urban areas across North America, CBC's Johanna Wagstaffe looks at new research that shows cities might actually be making fires worse.
Globe and Mail
20 hours ago
- Globe and Mail
Canada should invest in its research talent pipeline, says Canadian Institute For Advanced Research president
Stephen Toope, president of the Canadian Institute For Advanced Research, is a former vice-chancellor of Cambridge University and president of the University of British Columbia. He spoke to The Globe and Mail about the role of CIFAR, which brings people together from a range of disciplines to consider problems on the horizons of research, as a builder of scientific all-star teams. Dr. Toope also discussed the state of research in Canada and the U.S., as President Donald Trump has slashed billions in research funds and attacked several of the most prominent American universities, including Harvard. Q: What do you make of what has been happening between the U.S. government and Harvard? A: It's appalling. And it's not just about Harvard. Billions of dollars of research funding have been removed, arbitrarily, from a whole range of different universities, always for slightly different reasons that don't meet the desires of the U.S. administration. Q: You were invited to Ottawa for the Throne Speech. What are you hearing from the Government of Canada about its plans for research? A: There was a brief mention of research and innovation, rather high level, which was 'to build Canada into the world's leading hub for science and innovation.' That's great. We've also seen the decision to have a minister for artificial intelligence, which suggests a comfort level with trying to deploy new technologies. The proof will be in the pudding. Canada has some catch-up to play here. We have great strengths. We have a lot of solid and sometimes excellent universities. A lot of work needs to be done to make sure that our own ecosystem is strong and supporting research at an adequate level. Q: What does CIFAR do? We create networks of the very top people in the world who are interested in particular subjects. We bring them together across disciplines to try to unlock new approaches, new ideas, that are going to shape the future of research for decades to come. We're focused on some of the hardest questions facing science and humanity in the longer term. We draw the people who are in CIFAR networks from the university world – you might think of them as the all-star team – to work on these really tough questions. Q: How do you do manage an all-star team, and what are the challenges that come with it? The first thing is to conceptualize where we should be expending our resources and what kinds of networks should we bring together. Looking at the horizon and trying to figure out what are the really difficult questions that CIFAR should be looking at now, because they're going to play out importantly in the world over the next 20 to 50 years. That's job one. Job two is talent identification, making sure that we are well connected around the world, so that we know who's doing really exciting work and who has the impulse to work across disciplines collaboratively. Q: Can the world make up for the money being pulled out of U.S. research? No, that's a really important point to make. There's been some talk about how the universities will use some of their endowments, or the foundation world will step up. All of that money is a drop in the bucket, honestly, in relation to what has historically been the U.S. research endeavour. Q: What should Canada be doing in response? What do you think is a wise way to invest? I would start by analyzing where we are before we start inviting lots of new people into the system. Are we actually funding our research at the level that is necessary for a country with an advanced economy? I'm sad to say, I think the answer is no. There was a modest bump up in research funding in the last federal budget of the previous government, but we're still really not operating at the same level of support that many other countries are. We've got to analyze where we should be making core investments to ensure that our whole ecosystem is strong. If we do that, we could then think about some targeted investment to bring in new talent. If I were going to target the investment, I would say early- to mid-career researchers. I wouldn't be going after just two or three big names. Q: Why do you say early-career is better than an established star? Because you've got a longer runway if you can identify truly rising stars, and we've been good at that at CIFAR. If the government could think about a program designed to do that, then you've got people who are more likely to stay. If you invest in a person who's really very far advanced in their career, and then everything switches back with a new government in the U.S., it may be hard to hold on to those people. Q: Tell me about this year's Azrieli scholars, whose names were announced last month? This program is celebrating its 10th anniversary, and it's designed to identify really outstanding young researchers. What we're trying to do is wrap them around with support. So there's financial support to conduct their research, but more importantly there's skills support. How do you set up a lab effectively? How do you manage people? How do you establish priorities and stick with them? We encourage them to be bold, to work across disciplines and to be really ambitious. There are a number of published studies to indicate that despite all of the investment in science, we're actually getting results which are more and more incremental. We want to make sure that the next generation is encouraged to go for the breakthroughs. So we try to identify people from anywhere on the planet, and what they have in common is an aspiration to work across disciplines and a real, bold sensibility. Q: How do you know what a 'bold sensibility' looks like? It's usually around the ambition of the questions they're asking. One of the things CIFAR has been good at historically is pushing people to ask hard questions. Our very first program, 43 years ago, was artificial intelligence, robotics and society. That's pretty darn good in terms of foresight. We're trying to look for people who have that kind of questioning mind. They see an opportunity or challenge that other people haven't noticed yet. This interview has been edited and condensed.
